Radiomics Analysis for <sup>177</sup>Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer—A Model Based on Clinical Example
<sup>177</sup>Lu-DOTAGA-(l-y)fk(Sub-KuE) a.k.a. <sup>177</sup>Lu-PSMA I&T is currently used for radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers in Europe. Background: Dosimetry is mandatory according to EU guidelines...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/11/2/170 |